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Individuals living in regions of intense malaria transmission exhibit natural immunity that facilitates
persistence of parasitemia at controlled densities for much of the time without symptoms. This aspect of
immunity has been referred to as malarial “tolerance” and is thought to partly involve inhibition of the chain
of events initiated by a parasite toxin(s) that may otherwise result in cytokine release and symptoms such as
fever. Antibodies to the candidate Plasmodium falciparum glycosylphosphatidylinositol (GPI) toxin have been
viewed as likely mediators of such tolerance. In this study, the relationship between antibodies to P. falciparum
GPIs, age, and parasitemia was determined in asymptomatic children and adults living in Madang, Papua New
Guinea. The prevalence and intensity of antibody responses increased with age and were lowest in children 1
to 4 years old with the highest-density parasitemias. In children of this age group who were tolerant of
parasitemia during the study, only 8.3% had detectable immunoglobulin G (IgG) and none had IgM antibodies
to GPI. This suggests that anti-GPI antibodies are unlikely to be the sole mediator of malarial tolerance,
especially in children younger than 5 years. Following antimalarial treatment, clearance of parasitemia led to
a fall in anti-GPI IgG response in children and adolescents within 6 weeks. As anti-GPI antibodies potentially
play a role in protecting against disease progression, our results caution against the treatment of asymptomatic
parasitemia and suggest that generation of a sustained antibody response in children poses a challenge to novel
antitoxic vaccination strategies.
The natural history of malaria in regions of endemicity is
characterized by long periods of asymptomatic parasitemia
punctuated by episodic clinical attacks that decrease in fre-
quency with age (24, 33). This pattern has been explained by
the acquisition of exposure-related natural (or “clinical”) im-
munity that has been viewed for over 60 years as comprising
two major components: “antiparasitic” (i.e., the ability to con-
trol parasite densities) and “antitoxic” immunity (i.e., suppres-
sion of disease symptoms despite infection) (39). The ability of
individuals from regions of high endemicity to tolerate persis-
tent parasitemia without fever is considered to be a manifes-
tation of antitoxic immunity (17, 32). As the threshold of par-
asitemia associated with fever has been shown to be age
dependent and higher in children than in adults from geo-
graphically diverse locations (26, 32, 40, 45), it has been pro-
posed that this aspect of antitoxic immunity is most efficient in
childhood and declines with age (17).
Accumulating evidence has identified Plasmodium falcipa-
rum glycosylphosphatidylinositols (GPIs) as putative toxins
that initiate a number of cellular events that contribute to
malaria pathogenesis. Induction of the fever-producing cyto-
kines tumor necrosis factor alpha (TNF-) and interleukin-1
by mononuclear cells has been demonstrated in vitro (29, 34),
and transient pyrexia has been induced in vivo through admin-
istration of P. falciparum GPIs to mice (34). P. falciparum GPIs
have also been demonstrated to up-regulate expression of en-
dothelial cell surface receptors implicated in cytoadherence to
parasitized red cells (36) and to induce hypoglycemia (34)—
events implicated in the pathogenesis of severe malaria (15).
GPIs therefore represent an attractive immunological target
for strategies aimed at ameliorating disease due to P. falcipa-
rum (43).
Monoclonal antibodies to P. falciparum-derived GPIs have
been demonstrated to neutralize the TNF--inducing activity
of whole-parasite extracts in vitro (37), and a monoclonal an-
tibody recognizing phosphatidylinositol has been shown to in-
hibit TNF- induction by geographically diverse strains (3).
Polyclonal antibody raised in T-cell-deficient mice (5) and sera
from infected human patients with both P. falciparum and
Plasmodium vivax infection (4) have been reported to have
similar activity. On the basis of these studies, it has been
hypothesized that antibodies to GPIs play a role in mediating
tolerance of parasitemia and that their production would par-
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allel the densities of parasitemia observed in tolerant individ-
uals (32).
We hypothesized that individuals living in a region of intense
malaria transmission produce anti-GPI antibodies that are in-
duced by infection with P. falciparum. As threshold levels of
asymptomatic parasitemia are reported to decline with age (32,
40), we reasoned that the prevalence and level of P. falciparum
anti-GPI antibodies would be higher in children than in adults.
We tested these hypotheses by measuring immunoglobulin G
(IgG) and IgM responses against GPIs in different age groups
and investigated the association between antibody production
and parasitemia both cross-sectionally and longitudinally.
MATERIALS AND METHODS
Study site. Subjects were residents of two neighboring coastal villages (Haven
and Midiba) located approximately 20 km north of Madang township, Papua
New Guinea (PNG). The region is characterized by infection with all four human
malaria species, and there is little seasonal variation in parasitemia rates (12).
Residents are estimated to receive on average close to one infective bite per day
(10), with transmission highest during the wet season from October to May (11).
Study population. The study was conducted between February and May 2000
with ethical approval from the PNG Medical Research Advisory Committee and
the Ethics Committee of the Menzies School of Health Research, Darwin,
Australia. Following informed consent, nonpregnant adults and children who
were  1 year of age were screened using a clinical questionnaire administered
in the local language (Tok Pisin); measurement of axillary temperature; and
examination of a finger prick blood smear for malaria parasites. Enrollment was
confined to strictly defined asymptomatic subjects, with the selective aim of
including microscopically parasitemic and aparasitemic subjects and representa-
tion across different age groups. Participants were excluded from enrollment if
they were febrile (axillary temperature  37.5°C) at screening or on two subse-
quent occasions over the next 24 h; had taken antimalarials within 1 week; or had
a clinical history (fever, chills, sweats, headache, or myalgia) of recent (1 week)
malaria infection.
Peripheral blood smears were repeated at the time of venous blood collection
24 h after initial screening to account for periodic fluctuation of P. falciparum
density in particular (8, 18), and the combined readings were used to categorize
the parasite species present. Subjects with P. falciparum infection alone or in
combination with other species received a single dose of 25 mg of sulfadoxine per
kg of body weight and 1.25 mg of pyrimethamine (Fansidar; Roche, Dee Why,
Australia)/kg, and subjects with P. vivax, Plasmodium malariae, and/or Plasmo-
dium ovale were given three daily doses of chloroquine phosphate (Pharmamed,
Malta)/10 mg of kg. Subjects were followed up 6 weeks after enrollment using the
same procedures outlined above.
Specimen collection and processing. Thick and thin blood smears from all
screened and enrolled subjects were treated with a 4% Giemsa stain and were
examined by a field microscopist with over 15 years of experience (M. Lagog).
Smears were defined as negative if no parasites were seen in 100 high-power
(magnification, 1,000) oil immersion fields. Positive slides with scanty para-
sitemias (5 parasites/200 leukocytes) and a random 10% of all slides from
enrolled subjects were cross checked by a second microscopist (K. Lorry; 12 years
of experience), and discrepant slides were reviewed by both microscopists to
arrive at a final result. Venous blood was collected into sterile heparinized tubes
from which a manual leukocyte count was performed for calculation of parasite
densities (22). When a manual leukocyte count on the same day was unavailable
(25% of subjects), a subsequent manual count from the same person (taken 6
weeks later) was substituted, or an age-adjusted leukocyte count derived from
the study population was used. Plasma was separated by centrifugation and
stored at 70°C.
Antibody assays. Anti-GPI IgG and IgM antibodies were measured by en-
zyme-linked immunosorbent assay. The GPIs used in this study were purified by
high-performance liquid chromatography (HPLC) of the P. falciparum GPI-
enriched fraction obtained by solvent extraction procedures as described previ-
ously (29). The purity of the HPLC-purified GPIs was confirmed by carbohydrate
compositional analysis and thin-layer chromatography of similarly purified fatty
acid-labeled GPIs. The specificity of the seroreactivity of the HPLC-purified
GPIs has previously been established (29). The GPIs were coated at 1 and 2
ng/well for IgG and IgM assays, respectively; these coating concentrations give
saturated levels of seroreactivity. Tween 20 was included in the blocking buffer at
a concentration that reduced nonspecific binding (which was evident in a number
of subjects in preliminary experiments) without affecting the overall seroreactiv-
ity of samples or adherence of [3H]glucosamine-labeled GPIs to the enzyme-
linked immunosorbent assay plate (data not shown).
A stock solution of HPLC-purified GPIs was diluted with methanol and coated
at 25°C overnight onto half of a 96-well polystyrene microtiter plate (Maxisorb by
Nunc, N.Y.). Plates were washed once with 5% nonfat dairy milk in phosphate-
buffered saline, pH 7.2 (PBS) containing 0.05% Tween 20 (used for all subse-
quent washes and dilutions) and then blocked with 250 l of 5% nonfat dairy
milk in PBS containing 0.5% Tween 20 at 25°C for 2 h. Fifty microliters of
samples and controls (below) was added in duplicates at 1:100 dilution for IgG
and at 1:25 for IgM to GPI-coated and uncoated wells on the same plate and
were then incubated for 1 h at 25°C. Plates were washed five times, and their
contents were then incubated with 50 l of horseradish peroxidase-conjugated
goat anti-human IgG (heavy and light chains; Kirkegaard & Perry Laboratories,
Gaithersburg, Md.) or sheep anti-human IgM ( chain; Chemicon, Australia) at
1:2,000 dilution for 1 h at 25°C. Following five more washes (the last two in PBS,
pH 7.2, containing 0.05% Tween 20), optical densities were read at a wavelength
of 405 nm after 15 min of incubation with 50 l of 2,2-azino-di-(3-ethyl-benz-
thiazoline-6-sulfonate) substrate (Kirkegaard & Perry Laboratories). Finally,
background optical densities from uncoated wells were subtracted from those of
GPI-coated wells to adjust for nonspecific binding.
The optical densities from 15 non-malaria-exposed Australian adult controls
(mean age, 28 years [range, 20 to 44 years]; 33% male) were expressed as
percentages relative to malaria-exposed adult positive controls for both IgG and
IgM. As the results in Australian controls were normally distributed in both
assays, values of 2 standard deviations above the means were chosen as repre-
senting a cutoff between positive and negative and were arbitrarily assigned a
value of 1. The optical densities from all subjects, after controlling for nonspecific
binding, were similarly initially expressed as percentages relative to the positive
controls and then as multiples of the cutoff in Australian controls (i.e., values that
were  1 indicated positive results). Positive and negative controls were run on
each plate and showed acceptable variability between assays. Longitudinally
paired samples from the same individual were assayed concurrently on the same
plate.
Data analysis. Statistical analysis was performed using Stata version 6.0 (Stata
Corporation, Tex.). Age was stratified in subgroups consistent with earlier stud-
ies of malaria immunoepidemiology (20). Logistic regression was used to model
the relationship between antibody positivity, age, and parasitemia. Other pro-
portions were examined with the 	2 test or Fisher’s exact test (16). The intensity
of antibody response was correlated with age using Spearman’s rank test.
Changes in antibody response were analyzed longitudinally using the paired
Student’s t test or Wilcoxon test as appropriate for the distribution of data.
Two-sided P values of 0.05 were considered to indicate statistical significance.
RESULTS
Baseline characteristics. Single blood smears from 424 chil-
dren who were  1 year old (160 from Haven and 264 from
Midiba; 48.4% male) were screened by microscopy to enable
selection of subjects for enrollment. The proportion of subjects
positive for any malaria parasite at screening was highest in the
5- to 9-year age group (70.3%) and for P. falciparum in the 1-
to 4-year age group (50.8%). The prevalence of parasitemia in
different age groups, splenomegaly (82.7% in subjects who
were 14 years old, with a peak of 91.7% in children who were
5 to 9 years old), and stated bed net use (86.2% overall; 98.1%
in children who were 1 to 4 years old) was broadly consistent
with that found in previous data reported from this region (12,
17).
P. falciparum parasitemia was present in 116 (54%) of the
216 screened subjects who were initially enrolled into the
study. Venous blood collection was cancelled for 10 subjects
because of heavy rain, and another 20 were subsequently ex-
cluded (axillary temperature of 37.5°C in eight subjects; re-
cent malaria history in 12 subjects). Characteristics of the 186
subjects included in the study are given in Table 1. After
cross-checking and examination of the second smear, one or
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more additional parasite species were found in 21 of 77 (27%)
initially aparasitemic subjects and in 25 of 109 (23%) subjects
who were parasitemic on their screening smear. Three axillary
temperature readings were recorded in 151 subjects; two in 29
subjects; and one only in six subjects. It was not possible to
collect a second venous blood sample from all subjects due to
time constraints: follow-up samples taken at a median of 6
weeks after enrollment were available from 115 (62%) of the
186 subjects, nine of whom met the exclusion criteria at this
time point and were excluded from longitudinal analysis. Age,
gender, and baseline P. falciparum positivity did not differ
significantly between the groups for whom a second venous
sample was or was not available.
Relationship between anti-GPI antibody seropositivity and
age. The likelihood of anti-GPI IgG seropositivity increased
significantly with age: subjects from successive age groups (1 to
4, 5 to 9, 10 to 14, and 15 years) were 3.5 times likelier than
their immediate predecessors to be anti-GPI IgG positive
(odds ratio [OR], 3.5; 95% confidence interval [CI], 2.4 to 5.2;
P  0.001 [Fig. 1A]). The magnitude of this association was
unaltered after controlling for the nonsignificant effect of par-
asitemia with P. falciparum and/or other malaria parasites.
Baseline IgM antibody responses were tested in 128 (69%)
of the 186 included subjects. IgM antibodies to GPI were
absent in all subjects tested who were  5 years of age, and
although they increased across successive age groups, IgM
seroprevalence was much less than that of IgG (Fig. 1B). After
controlling for the significant effect of P. falciparum para-
sitemia (below), subjects who were  20 years were 10 times
likelier than younger subjects to be IgM antibody positive (OR,
10; 95% CI, 3.3 to 30.4; P  0.001).
The proportion of subjects with higher-intensity IgG anti-
body responses increased across successive age groups (Fig.
2A). The intensity of anti-GPI IgG response was positively
correlated with age, grouped 1 to 4, 5 to 9, 10 to 14, 15 to 19,
and 20 years (Spearman’s correlation coefficient, 0.55; P 
0.001). IgM antibody responses also increased with advancing
age but were not analyzed statistically due to the lower num-
bers of child and adolescent subjects positive for IgM antibod-
ies (Fig. 2B).
Cross-sectional relationship between anti-GPI antibody re-
sponse and parasitemia. There was no association between the
prevalence of P. falciparum parasitemia and anti-GPI IgG se-
ropositivity at enrollment. Twelve of 19 (63.2%) 1- to 4-year-
old subjects had P. falciparum parasitemia, but only one (8.3%)
had IgG and none had IgM. In contrast, 47 of 71 subjects
(66.2%) who were  20 years old had no P. falciparum para-
sitemia in their blood smear, yet 42 (89.4%) had anti-GPI
FIG. 1. Percentage of subjects positive for IgG antibodies to GPIs (means  standard errors [S.E.]) (A) and IgM antibodies (B). Diamonds
represent the percentage of subjects with P. falciparum (Pf) parasitemia either alone or in combination with other parasites for each age group;
squares represent the geometric mean density of parasitemia (solid line).
TABLE 1. Baseline characteristics of 186 subjects included in the study
Age group
(yr) n
Subject
mean age
(yr [95% CI])
%
Male
No. of subjects with combined parasitemia on paired blood smearsa Results forP. falciparumb
P.f P.f/P.v P.f/P.m P.f/P.v/P.m P.f/P.v/P.o P.v P.v/P.m P.m P.o Neg n % P.f/lc
1–4 19 2.8 (2.4–3.3) 26.3 9 3 0 0 0 4 0 0 0 3 12 63.2 1,199
5–9 36 7.2 (6.7–7.7) 50.0 13 7 3 2 0 5 0 1 0 5 25 69.4 431
10–14 37 11.8 (11.3–12.3) 54.1 10 6 4 1 1 4 1 3 0 7 22 59.5 281
15–19 23 17.0 (16.2–17.7) 39.1 11 2 1 1 1 0 0 0 0 7 16 69.6 163
20 71 31.6 (29.1–34) 46.5 20 3 0 1 0 9 2 1 1 34 24 33.8 103
a Number of subjects with each species (or combined species) of parasite on examination of two consecutive daily blood smears. P.f 
 P. falciparum; P.v 
 P. vivax;
P.m 
 P. malariae; P.o 
 P. ovale; and Neg 
 negative for parasites.
b Number (n) and percentage (%) of subjects with P. falciparum parasitemia either as the sole infecting parasite or in combination with other parasites.
c P.f/l is the geometric mean of the highest-density Plasmodium falciparum parasitemia measured from two consecutive daily blood smears.
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IgGs. No association was observed between blood smear pos-
itivity for other malaria parasites and anti-GPI IgGs (data not
shown), although these analyses may have been underpowered
due to low numbers (Table 1).
In subjects aged20 years, 56.5% (13 of 23) of subjects with
P. falciparum parasitemia (alone or in combination with other
parasites) were IgM positive compared to 25% (9 of 36) with-
out P. falciparum (including aparasitemic subjects [OR, 3.9;
95% CI, 1.3 to 11.9; P 
 0.015; 	2 test]). Excluding subjects
with mixed infections, anti-GPI IgMs were present in 55.6%
(10 of 18) of subjects aged 20 years with P. falciparum par-
asitemia, compared to 0 of 7 subjects with P. vivax (P 
 0.02;
Fisher’s exact test). The relationship between anti-GPI IgM
positivity and parasitemia was not examined in subjects aged
20 years due to the small number of subjects positive for IgM
antibodies (5 of 69; 7.2%).
Longitudinal antibody response to GPI following clearance
of parasitemia. Paired antibody responses were examined in
subjects whose baseline P. falciparum parasitemia was cleared
by treatment with standard antimalarials (verified on two con-
secutive daily blood smears after 2 weeks) and in whom no
recrudescence or reinfection with P. falciparum was noted at
follow-up. All 18 seronegative subjects with P. falciparum par-
asitemia at baseline remained seronegative at follow-up and
were therefore not included in this analysis.
Eradication of P. falciparum parasitemia was associated with
a mean fall in IgG antibody response of 30% (95% CI, 17 to
43%) relative to baseline after a median of 6 weeks (interquar-
tile range, 5 to 8 weeks; P  0.001) in 31 subjects who were
initially antibody positive. Antibody responses decreased in 17
of 19 subjects aged 20 years by a mean of 48% (95% CI, 36
to 60.1%; P  0.001) but were unchanged in the 12 subjects
aged20 years (median increase, 1%; P
 0.39). There was no
change in IgG responses in 26 control subjects without P.
falciparum parasitemia at either time point, either overall
(mean decrease, 3.6%; P 
 0.55) or in age-based subgroups.
DISCUSSION
This study demonstrates for the first time that, in a cohort of
children and adults with intense malaria exposure, the pres-
ence of anti-GPI antibodies is directly associated with P. falci-
parum parasitemia. Eradication of asymptomatic P. falciparum
infection in subjects who were  20 years of age was followed
by a decrease in IgG antibody responses, whereas there was no
change in older subjects. Blood smear positivity with P. falci-
parum was associated with the presence of IgM antibodies to
GPIs in subjects aged 20 years. Together these observations
indicate that P. falciparum can induce both IgM and IgG an-
tibodies to its GPIs and that the IgG response is more persis-
tent in adulthood.
There are a number of possible reasons for the lack of a
cross-sectional association between blood smear positivity for
P. falciparum and anti-GPI IgGs. Children and adolescents
aged 4 to 14 years from Madang Province have frequent sub-
patent infections (i.e., PCR positive/microscopy negative) (9)
that could induce antibody production, as do adults from a
nearby region (25). Almost all subjects who were  15 years
old were IgG positive, which is likely to reflect an increasing
persistence of antibody response between infections, thus mak-
ing an association with parasitemia more difficult to detect.
The association between anti-GPI IgM and parasitemia in sub-
jects aged 20 years may have been more evident due to an
increased likelihood of IgM responses coinciding with infec-
tion, as IgM responses are generally of shorter duration than
those of IgG (21).
Although the numbers were relatively small, we could find
no evidence to support previous suggestions that P. vivax in-
duces antibodies that are cross-reactive with P. falciparum
GPIs (4, 6). In our study, IgM anti-GPI antibody responses
were absent in subjects aged 20 years with P. vivax infection
but were present in a majority of subjects with P. falciparum
infection and in almost one-third of those who were apara-
sitemic. The positive responses seen in aparasitemic subjects
FIG. 2. Intensity of IgG antibody response to GPI (A) and IgM antibody responses (B). The upper limit (mean plus 2 standard deviations) of
the responses in 15 non-malaria-exposed Australian adult controls was arbitrarily assigned a value of 1, and antibody responses in study subjects
were expressed as a multiple of this value (units). Positive responses of increasing intensity are shown in progressively darker shades. Negative
responses (Neg) represent adjusted absorbance readings less than the upper limit of the nonexposed controls (i.e.,  1 U).
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may reflect recently eliminated and/or subpatent P. falciparum
infection. In contrast, the lack of IgM response in those with P.
vivax is consistent with the recent demonstration of species-
transcending regulation of parasite density in this region,
which results in significantly more sequential interspecies in-
fections than in concurrent ones (7).
The prevalence and intensity of anti-GPI IgG and IgM re-
sponses to purified GPIs in the study population were posi-
tively related to age, consistent with a recent report from
Kenya (29). This pattern was the inverse of mean parasitemia
levels and also of the negative relationship previously demon-
strated between age and parasite density in self-reporting fe-
brile cases from Madang (17). In two other studies of popula-
tions resident in a nearby region in PNG (40) and an African
region of holoendemicity (32), children under 5 years of age
(although suffering more frequent clinical attacks) were shown
to tolerate higher levels of parasitemia during asymptomatic
infections than were older children and adults. These observa-
tions are consistent with earlier reports (26, 45) and support
the general view that the ability to regulate parasite densities at
lower levels during asymptomatic infections increases with age
but that antitoxic immunity diminishes, as reflected by a de-
creasing fever threshold (17). If this is correct, then our finding
that anti-GPI antibody responses were uncommon in tolerant
children aged 5 years but were abundant in adults would
suggest that these antibodies are unlikely to be the sole medi-
ator of parasite tolerance and at most play a minor role in the
youngest children.
Longitudinal studies may clarify what role anti-GPI antibod-
ies play in natural immunity to malaria. As the pathophysiology
of severe malaria is dependent on cytoadherence and local
cytokine production (24), it is possible that these antibodies act
to prevent disease progression by down-regulating the pro-
cesses that lead to both of these events (34, 36). This potential
role is consistent with recent epidemiological interpretations of
the nature of clinical immunity to malaria (19, 41), and our
data suggest that it would be likely to be more efficient in older
children and adults than in children aged 5 years. Further-
more, our finding that anti-GPI antibodies increase with age
concurrent with a decline in parasite density raises the possi-
bility that these antibodies contribute to antiparasitic immu-
nity. As the role of anti-GPI antibodies is presently unclear,
our finding that anti-GPI IgG responses to P. falciparum are
less persistent in children and adolescents provides further
caution against the treatment of asymptomatic parasitemia in
these age groups (13).
GPIs have been considered prime candidate molecules for
vaccination strategies (43) that aim to diminish the manifesta-
tions of disease rather than protect against parasitemia (30). If
anti-GPI antibodies can be shown to protect against disease
progression, then generating a sustained antibody response in
children  5 years of age will be a priority. Understanding the
events involved in GPI antigen presentation and processing
(28, 31, 35, 38) and whether they may be modified by adjuvants
or immunomodulators (27, 44) may help improve vaccine im-
munogenicity in this age group. P. falciparum GPIs have been
shown to induce production of nitric oxide by macrophages
and endothelial cells in vitro (42), and systemic production of
NO has been proposed to mediate tolerance of parasitemia (1,
2, 14) and to protect against uncomplicated and cerebral ma-
laria (1) in young children. Active vaccination against GPI
antigens may theoretically interfere with this mechanism of
antitoxic immunity in addition to other potentially beneficial
cytokine responses induced by GPIs (such as regulation of
parasite density [23]).
In summary, our data show that individuals living in a region
of high malaria endemicity produce in response to infection
antibodies to P. falciparum GPIs that are more easily elicited,
of higher intensity, and more persistent with increasing age.
Our data suggest that other mechanism(s) of antitoxic immu-
nity are likelier to mediate tolerance of parasitemia in young
children but do not exclude a role for anti-GPI antibodies in
modifying the risk or outcome of clinical malaria in those
individuals who produce the antibodies. Until the role of anti-
GPI antibodies is clarified, our results caution against the
clearance of asymptomatic parasitemia in children and adoles-
cents in whom possible protective effects may be reduced by
treatment. Longitudinal studies that correlate natural produc-
tion of anti-GPI antibodies with disease risk and severity in
different age groups may help to inform potential vaccination
strategies targeting P. falciparum GPIs.
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